Y-mAbs Therapeutics Acquired by SERB Pharmaceuticals in $412 Million Buyout Following Strategic Review
SERB Pharmaceuticals agreed to acquire Y-mAbs Therapeutics in an all-cash transaction valued at approximately $412 million12345.
Under the merger, Y-mAbs shareholders will receive $8.60 per share, representing a 105% premium to the August 4, 2025 closing price12345.
The acquisition will include Y-mAbs' lead oncology asset, Danyelza (naxitamab-gqgk), further broadening SERB’s rare disease portfolio135.
Y-mAbs' Board of Directors unanimously approved the SERB transaction after a strategic review and discussions with potential buyers and financing sources134.
Y-mAbs stockholders holding about 16% of outstanding shares have already agreed to tender their shares in favor of the SERB offer5.
The transaction is expected to close by the fourth quarter of 2025, pending customary closing conditions13.
The deal positions SERB as a stronger player in rare diseases and medical emergencies, expanding its investment and presence in the U.S. market13.
Sources:
1. https://www.worldpharmaceuticals.net/news/serb-pharma-to-acquire-y-mabs-therapeutics-for-412m/
2. https://www.ainvest.com/news/mabs-acquired-serb-8-60-share-shares-surge-100-2508/
3. https://ir.ymabs.com/news-releases/news-release-details/serb-pharmaceuticals-agrees-acquire-y-mabs-therapeutics-0